โ
๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข Adjusted EPS: $0.77 (Est. $0.68) โ
โข Revenue: $15.03B (Est. $14.39B) โ
โข Launched and acquired products revenue grew 18% operationally.
โข Excluding Comirnaty and Paxlovid, revenue increased 5% operationally.
โข Reported EPS: -$0.04, reflecting $4.3B of non-cash intangible asset impairments.
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐
โข FY2026 revenue: $60.5Bโ$62.5B (Midpoint: $61.5B vs. Est. $61.74B) ๐ฐ
โข FY2026 Adjusted EPS: $2.80โ$3.00 (Midpoint: $2.90 vs. Est. $2.95) ๐ฐ
โข Raised the midpoint of FY2026 revenue guidance by $500M while reaffirming Adjusted EPS guidance.
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Revenue increased 3% YoY to $15.03B, driven by continued strength in Eliquis, Padcev, Vyndaqel and Lorbrena.
โข COVID product headwinds continued, with Paxlovid revenue down 95% operationally and Comirnaty down 34% operationally.
โข Announced an additional $2.5B of productivity savings expected to be realized between 2027 and 2029.
โข Advanced its late-stage pipeline with several pivotal readouts expected over the next 12 months.
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
CEO Albert Bourla said Pfizer delivered another strong quarter as launched and acquired products continued to perform well, while the obesity pipeline and oncology portfolio strengthened confidence in the company's long-term growth strategy.
